Salix Pharmaceuticals Ltd. (SLXP) posted a third quarter loss of $7.3 million or $0.15 per share, compared to a loss of $5.4 million or $0.11 per share in the prior year period.
On average, nine analysts polled by Thomson Reuters expected the company to report a loss of $0.29 per share. Analysts' estimates typically exclude special items.
Total product revenue for the quarter was $65.7 million, compared to $42.9 million in last year period. Nine Wall Street analysts expected revenues of $60.42 million.
Looking forward, for the fourth quarter, the company expects product revenue to be approximately $68 million and a loss of approximately $0.14 per share.
Street analysts expect a loss of $0.03 per share on revenues of $72.28 million.
Further ahead, for the fiscal year 2009, the company expects total product revenue to be approximately $230 million, and a loss of approximately $0.90 per share.
Street analysts expect a loss of $0.92 per share on revenues of $230.18 million.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.